Washington, D.C. (May 5, 2014) — America’s biopharmaceutical research companies currently are developing 119 novel new medicines to help improve the lives of the estimated 61.5 million Americans that are affected by mental health disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 36 for schizophrenia, 29 for depression, 20 for substance/addictive disorders, 15 for attention deficit/hyperactivity disorder and 15 for anxiety disorders.
Mental health conditions pose a heavy human and economic burden in the United States. According to the National Institute of Mental Health (NIMH), 1 in 4 American adults have been diagnosed with a mental health disorder – and serious mental illnesses cost the U.S. more than $317 billion annually in lost wages, health care expenditures and disability benefits.
“As our knowledge of the brain continues to expand, biopharmaceutical scientists are finding new, exciting ways to help patients facing depression, schizophrenia and many other disorders,” said PhRMA President and CEO John J. Castellani. “The more than 100 medicines in development today represent tremendous hope for patients, our health care system and our economy.”
Biopharmaceutical research companies, working in collaboration with academia, government researchers, patient organizations and others in the innovation ecosystem, are applying new scientific approaches and evolving knowledge of disease to bring new solutions to patients who face mental disorders such as anxiety, depression, schizophrenia or substance use disorders.
The new report conveys an array of innovative approaches being pursed to treat many of these disorders. Examples include:
- A medicine that may provide a broader spectrum of therapeutic activity for attention-deficit/hyperactivity disorder (ADHD).
- An intranasal medicine for treatment-resistant depression that may offer a rapid onset of therapeutic effects.
- A medicine for schizophrenia that potentially could result in fewer negative side effects than existing treatments.
In addition to information on some of the medicines in the pipeline, the new report delves into challenges unique to the research and development of mental health treatments, collaborative research partnerships that are helping advance science, early scientific discoveries that are raising our understanding of mental health conditions, the importance of adherence to medicines for mental health disorders, and comprehensive facts about mental health in the United States.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.
Find PhRMA Online:
For information on how innovative medicines save lives, visit: http://www.innovation.org
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org